Control lighting condition then Active light intervention for Alzheimer's Disease (AD)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Light and Health Research Center, Menands, NY
Alzheimer's Disease (AD)+2 More
Control lighting intervention - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

To test the effect of a tailored lighting intervention controlled by the Readings At Desk (RAD) controller on sleep and mood in Alzheimer's disease participants.

Eligible Conditions

  • Alzheimer's Disease (AD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Alzheimer's Disease (AD)

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: up to 22 weeks

up to 22 weeks
Depression screening utilizing the Cornell Scale for Depression in Dementia (CSDD)
Sleep disturbance using the Pittsburgh Sleep Quality Index
Sleep efficiency measured by actigraphy

Trial Safety

Safety Progress

1 of 3

Other trials for Alzheimer's Disease (AD)

Trial Design

2 Treatment Groups

Control lighting condition then Active light intervention
1 of 2
Active lighting intervention then Control lighting condition
1 of 2
Active Control

30 Total Participants · 2 Treatment Groups

Primary Treatment: Control lighting condition then Active light intervention · No Placebo Group · N/A

Control lighting condition then Active light interventionActiveComparator Group · 2 Interventions: Control lighting intervention, Active lighting intervention · Intervention Types: Device, Device
Active lighting intervention then Control lighting conditionActiveComparator Group · 2 Interventions: Control lighting intervention, Active lighting intervention · Intervention Types: Device, Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 22 weeks

Trial Background

Prof. Mariana Figueiro, Professor
Principal Investigator
Icahn School of Medicine at Mount Sinai
Closest Location: Light and Health Research Center · Menands, NY
N/AFirst Recorded Clinical Trial
1 TrialsResearching Alzheimer's Disease (AD)
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a diagnosis of Alzheimer's disease with a Mini Mental Score Examination (MMSE) between 0 and 19.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.